Cargando…

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer

OBJECTIVES: Adjuvant paclitaxel and trastuzumab has been shown to be an effective regimen with low risk of cancer recurrence and treatment-related toxicities in early-stage node-negative, HER2-positive breast cancer. We investigated the cost-effectiveness of this regimen. METHODS: A Markov-based mic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hajjar, Ali, Ergun, Mehmet A., Alagoz, Oguzhan, Rampurwala, Murtuza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550431/ https://www.ncbi.nlm.nih.gov/pubmed/31166995 http://dx.doi.org/10.1371/journal.pone.0217778

Ejemplares similares

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013)

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
por: Genuino, Anne Julienne, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
por: Tran, Phuong T., et al.
Publicado: (2020)

Update on Adjuvant Chemotherapy for Early Breast Cancer
por: Rampurwala, Murtuza M, et al.
Publicado: (2014)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2022)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
por: Xu, Qiaoping, et al.
Publicado: (2021)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
por: Simoens, Steven, et al.
Publicado: (2021)

Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab
por: Ding, Jinhua, et al.
Publicado: (2017)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
por: Nieto, Celia, et al.
Publicado: (2019)

Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
por: Goldvaser, Hadar, et al.
Publicado: (2019)

Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis
por: Genuino, Anne Julienne, et al.
Publicado: (2019)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
por: Lluch-Gómez, J., et al.
Publicado: (2023)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis
por: Leung, William, et al.
Publicado: (2016)

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
por: Pegram, Mark D., et al.
Publicado: (2018)

Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer
por: Gershon, Noga, et al.
Publicado: (2019)

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019)

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2016)

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
por: Patel, Tejal A., et al.
Publicado: (2019)

Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
por: Cao, Lu, et al.
Publicado: (2016)

Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
por: Sardesai, Sagar, et al.
Publicado: (2020)

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
por: Ansaripour, Amir, et al.
Publicado: (2017)

Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report
por: Papageorgiou, Konstantinos I, et al.
Publicado: (2009)

Successful Treatment of HER2-neu–positive Breast Cancer With Paclitaxel and Trastuzumab Supplemented With Turkey Tail Mushrooms and Community Support
por: Smith, Julie
Publicado: (2012)

Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”
por: Baselga, J., et al.
Publicado: (2019)

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
por: Waks, Adrienne G., et al.
Publicado: (2022)

Optimize the combination regimen of Trastuzumab and Nab-paclitaxel in HER2-positive tumors via modulating Caveolin-1 expression by lovastatin
por: Yang, Canyu, et al.
Publicado: (2022)

Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study
por: Li, Junjie, et al.
Publicado: (2018)

How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?
por: Morganti, S., et al.
Publicado: (2022)

Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size
por: Bender, Laura, et al.
Publicado: (2020)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
por: Viani, Gustavo A, et al.
Publicado: (2007)

Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial
por: Shen, Songjie, et al.
Publicado: (2017)

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab
por: Jacquinot, Quentin, et al.
Publicado: (2022)

Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma
por: Zhang, Liangze, et al.
Publicado: (2017)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sjlc5r7f0r9b7ncimv9da96r2u